Accelerate neutrophil recovery with AMGOFIL
  • Chemotherapy-induced neutropenia is a common and serious complication of myelosuppressive chemotherapy. It is associated with significant morbidity and mortality, and can increase the overall cost of providing cancer therapy. Filgrastim reduces the incidence of infection related morbidity & mortality in patients with febrile neutropenia. [5]
  • [5] Ref: The New England Journal of Medicine 1991; 325:164-70

AMGOFIL 300mcg/ml

Recombinant Human Granulocyte Colony Stimulating Factor

For Intravenous or Subcutaneous use

Neutrophils Keep Growing with Amgofil!


The use of AMGOFIL:
Reduces the incidence of infection related morbidity & mortality in patients with febrile neutropenia.

• Statically significant reduction from 77% in placebo group to 40% in Filgrastim group. [10]
• Filgrastim used for ≥ 7 days had a lower incidence of febrile neutropenia compared with dosing of < 7 days. [11]

Allows cancer patients to get an earlier & more rapid neutrophil recovery and continue safely on DOSE INTENSE THERAPY.

• A transient increase in neutrophil count is seen in 1-2 days after initiation of Filgrastim therapy. To ensure a sustained therapeutic response, it should be administered daily for 2 weeks or until ANC reaches normal limit. [10]
• If patients continue chemotherapy without Filgrastim, there is 50% decrease in neutrophil count within 1-2 days, with a return to pretreatment level within 7 days.

Brief Prescribing Information:

AMGOFIL(Filgrastim), Indications: For the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. For the mobilization of the peripheral blood progenitor cells (PBPC). In patients, children's or adults, with severe congenital, cyclic, or idiopathic neutropenia with an ANC of 0.5X 109/, and a history of severe or recurrent infections, long term administration of AMGOFIL is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events. AMGOFIL is indicated for the treatment of persistent neutropenia (ANC < 1.0 X 109/L) in patients with advanced HIV infection, in order to reduced the risk of bacterial infection when other option to manage neutropenia are inappropriate. Side Effects: Nausea/Vomiting, Skeletal pain, Alopecia, Diarrhea. Dosage & Administration: Recommended dose of AMGOFIL is 0.5MIU (5pg)/kg/day. The first dose of AMGOFIL should not be administered less than 24 hrs following cytotoxic chemotherapy. How Supplied: Each 1 ml single use vial contains 300 pg (30 million units) of Filgrastim. Storage Condition: Store below 2 to 8°C. DO NOT FREEZE. MRP Rs. 3300.

Ref: [10] Crawford J, et al, N Engl J Med. 1991;325: 164-170.
[11] Scott SD, et al, J Manag Care Pharm. 2003;9(suppl 2): 15-21.

Business Relationship

The path from a potential break through to a successful global brand depends
on securing the necessary resources, expertise and experiences.

Best Medical Services

Product Portfolio